Singapore: Manufacturing Outlook remains gloomy – UOB
|Senior Economist at UOB Group Alvin Liew comments on the release of Industrial Production readings in Singapore.
Key Takeaways
“Singapore’s industrial production (IP) extended its weakness with a -11.7% m/m SA, -8.9% y/y decline in Feb, from a revised -0.4% m/m, -3.1% y/y in Jan. The Feb contraction was way worse than Bloomberg’s median forecast of +1.1% m/m, 1.8% y/y but close to our forecast of -10.7% y/y. This was the fifth consecutive month of y/y decline and the worst streak since 2015. Excluding the volatile biomedical manufacturing, IP contracted by a smaller -4.9% y/y in Feb (from 7.1% y/y in Jan).”
“The Feb IP was weighed lower by sharper declines in electronics (-10% y/y from -4.8% in Jan) and chemicals (-14.9% y/y from -13.1% in Jan), while biomedical manufacturing output crashed heavily by -33.6% y/y, solely due to a -59% y/y plunge in pharmaceuticals output, its worst contraction since Jul 2008 (-69.6% y/y).”
“IP Outlook – Even if we excluded the volatility brought by the biomedical manufacturing component, the latest Feb IP print continues to affirm our downbeat manufacturing outlook, and thus, we maintain our forecast for Singapore 2023 manufacturing to contract by 5.4% due to the worsening electronics downcycle and weaker external demand. Cracks in the export outlook also became more pronounced with non-oil domestic exports (NODX) recording consecutive, deeper y/y contractions since Aug 2022. We are likely to see a few more months of y/y declines in NODX before improving in the 2H. We expect full year NODX to contract by -5.5% in 2023. In line with the negative trade and manufacturing projections, we also keep our modest 2023 GDP growth forecast of 0.7% (closer to the lower end of the official forecast range of 0.5-2.5%).”
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.